CareDx Inc
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution … Read more
CareDx Inc (CDNA) - Net Assets
Latest net assets as of September 2025: $311.14 Million USD
Based on the latest financial reports, CareDx Inc (CDNA) has net assets worth $311.14 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($432.31 Million) and total liabilities ($121.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $311.14 Million |
| % of Total Assets | 71.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | 36.28% |
| 10-Year Change | 1183.08% |
| Growth Volatility | 81.15 |
CareDx Inc - Net Assets Trend (2012–2024)
This chart illustrates how CareDx Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CareDx Inc (2012–2024)
The table below shows the annual net assets of CareDx Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $378.43 Million | +44.81% |
| 2023-12-31 | $261.33 Million | -39.35% |
| 2022-12-31 | $430.91 Million | -7.51% |
| 2021-12-31 | $465.88 Million | +67.78% |
| 2020-12-31 | $277.68 Million | +180.48% |
| 2019-12-31 | $99.00 Million | +3.20% |
| 2018-12-31 | $95.93 Million | +1711.15% |
| 2017-12-31 | $-5.95 Million | -130.13% |
| 2016-12-31 | $19.76 Million | -33.00% |
| 2015-12-31 | $29.49 Million | -28.58% |
| 2014-12-31 | $41.30 Million | +127.41% |
| 2013-12-31 | $-150.67 Million | -2.36% |
| 2012-12-31 | $-147.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CareDx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46962800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $51.00K | 0.01% |
| Other Comprehensive Income | $-8.57 Million | -2.26% |
| Other Components | $1.01 Billion | 267.73% |
| Total Equity | $378.43 Million | 100.00% |
CareDx Inc Competitors by Market Cap
The table below lists competitors of CareDx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sino Wealth Electronic Ltd
SHE:300327
|
$878.85 Million |
|
Hiconics Drive Tech Co
SHE:300048
|
$879.16 Million |
|
Gujarat State Petronet Limited
NSE:GSPL
|
$879.26 Million |
|
SIMMTECH Co. Ltd
KQ:222800
|
$879.62 Million |
|
Corporación Interamericana de Entretenimiento S.A.B. de C.V
MX:CIEB
|
$878.70 Million |
|
Teemsun Technology Co.,Ltd
SHE:301571
|
$878.59 Million |
|
Raven Industries Inc
F:RV1
|
$878.49 Million |
|
Bajaj Housing Finance
NSE:BAJAJHFL
|
$877.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CareDx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 261,328,000 to 378,433,000, a change of 117,105,000 (44.8%).
- Net income of 52,549,000 contributed positively to equity growth.
- Share repurchases of 522,000 reduced equity.
- Other comprehensive income decreased equity by 1,606,000.
- Other factors increased equity by 66,684,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $52.55 Million | +13.89% |
| Share Repurchases | $522.00K | -0.14% |
| Other Comprehensive Income | $-1.61 Million | -0.42% |
| Other Changes | $66.68 Million | +17.62% |
| Total Change | $- | 44.81% |
Book Value vs Market Value Analysis
This analysis compares CareDx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-19.97 | $17.60 | x |
| 2013-12-31 | $-20.44 | $17.60 | x |
| 2014-12-31 | $4.45 | $17.60 | x |
| 2015-12-31 | $2.49 | $17.60 | x |
| 2016-12-31 | $1.18 | $17.60 | x |
| 2017-12-31 | $-0.26 | $17.60 | x |
| 2018-12-31 | $2.69 | $17.60 | x |
| 2019-12-31 | $2.35 | $17.60 | x |
| 2020-12-31 | $5.97 | $17.60 | x |
| 2021-12-31 | $8.92 | $17.60 | x |
| 2022-12-31 | $8.08 | $17.60 | x |
| 2023-12-31 | $4.86 | $17.60 | x |
| 2024-12-31 | $6.68 | $17.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CareDx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.89%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.74%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.30x
- Recent ROE (13.89%) is above the historical average (-31.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -24.74% | 2.07x | 0.00x | $9.66 Million |
| 2013 | 0.00% | -16.03% | 2.24x | 0.00x | $11.53 Million |
| 2014 | 1.89% | 2.86% | 0.45x | 1.48x | $-3.35 Million |
| 2015 | -46.47% | -48.70% | 0.51x | 1.89x | $-16.66 Million |
| 2016 | -202.59% | -97.14% | 0.53x | 3.94x | $-41.42 Million |
| 2017 | 0.00% | -114.79% | 0.58x | 0.00x | $-54.86 Million |
| 2018 | -48.74% | -61.06% | 0.59x | 1.36x | $-56.35 Million |
| 2019 | -22.19% | -17.29% | 0.84x | 1.53x | $-31.87 Million |
| 2020 | -6.74% | -9.74% | 0.52x | 1.33x | $-46.48 Million |
| 2021 | -6.58% | -10.34% | 0.52x | 1.22x | $-77.25 Million |
| 2022 | -17.78% | -23.81% | 0.59x | 1.26x | $-119.70 Million |
| 2023 | -72.81% | -67.88% | 0.60x | 1.79x | $-216.42 Million |
| 2024 | 13.89% | 15.74% | 0.68x | 1.30x | $14.71 Million |
Industry Comparison
This section compares CareDx Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CareDx Inc (CDNA) | $311.14 Million | 0.00% | 0.39x | $878.73 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |